Albumin inhibits apolipoprotein AI and AII production in human hepatoblastoma cell line (Hep G2): Additive effects of oleate-albumin complex

Atherosclerosis

Volumn 149, Issue 1, 2000, Pages 43-49

  Sakai, Takaaki ^a,b   Jin, Fu You ^a,b   Kamanna, Vaijinath S ^a,b   Kashyap, Moti L ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Albumin; Apolipoprotein AI; Apolipoprotein AII; Fatty acids; HDL1

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; OLEIC ACID;

ALBUMIN BLOOD LEVEL; ARTICLE; CELL METABOLISM; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LIVER CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ALBUMINS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; OLEIC ACID; PROBABILITY; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0034004357     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00292-0     Document Type: Article

References (40)

1. Miller G.J., Miller N.E. Plasma high density lipoprotein concentration of ischemic heart disease. Lancet. 1:1975;16.
2. Castelli W.P., Doyle J.T., Gordon T., Hames C.G., Hjortland M.C., Hully S.B. HDL cholesterol and other lipids in coronary heart disease: the cooperative lipoprotein phenotyping study. Circulation. 55:1977;767.
3. Gordon T., Castelli W.P., Hjortland M.C., Kannnel W.B., Dawber T.R. High density lipoprotein as a protective factor against heart disease: the Framingham Heart Study. Am. J. Cardiol. 62:1977;707.
4. Fielding C.J., Fielding P.E. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc. Natl. Acad. Sci. USA. 78:1981;3911.
5. Kashyap M.L. Basic considerations in the reversal of atherosclerosis: significance of high density lipoproteins in stimulating reverse cholesterol transport. Am. J. Cardiol. 63:1989;56H.
6. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265.
7. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91:1994;9607.
8. Saku K., Ahmad M., Glas-Greenwalt P., Kashyap M.L. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb. Res. 39:1985;1.
9. Yoi Y. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (apo A-I). J. Clin. Invest. 82:1988;803.
10. Warden C.H., Kedrick C.C., Qiao J.H., Castellani L.W., Lusis A.J. Atherosclerosis in transgenic mice overexpressing apolipoprotein AII. Science. 261:1993;469.
11. Castellani L.W., Navab M., Lenten B.J.V., Hedrick C.C., Hama S.Y., Goto A.M., Fogelman A.M., Lusis A.J. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J. Clin. Invest. 100(2):1997;464.
12. Jin F.-Y., Kamanna V.S., Kashyap M.L. Estradiol stimulates apolipoprotein AI but not AII-containing particle synthesis and secretion by stimulating mRNA transcription rate in the Hep G2 cells. Arterioscler. Thromb. Vasc. Biol. 18:1998;999.
13. Tam S.-P., Archer T.K., Deeley R.G. Effects of estrogen on apolipoprotein secretion by the human hepatocarcinoma cell line, Hep G2. J. Biol. Chem. 260:1985;1670.
14. Kempen H.J., Imbach A.P., Giller T., Neumann W.J., Hennes U., Nakada N. Secretion of apolipoprotein A-I and B by Hep G2 cells: regulation by substrates and metabolic inhibitors. J. Lipid Res. 36:1995;1796.
15. Van Zoren D., Adams L.E., Hynd B.A., Hess E.V., Kashyap M.L. Tissue lipoprotein lipase, serum and urinary cholesterol, triglycerides and high density lipoprotein metabolism in renal tubular antigen induced nephrotic syndrome (Heymann's nephritis). Biochem. Med. 25:1981;260.
16. Saku K., Mendoza S.G., Laver M., Hynd B.A., Gartside P.S., Kashyap M.L. High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria. Nephron. 50:1988;112.
17. Sun X., Jones H., Joles J.A., Van Tol A., Kaysen G.A. Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am. J. Physiol. 262:1992;F755.
18. Rothwell T.C., Kamanna V.S., Jin F.Y., Koren E., Foley T., Kashyap M.L. Characterization of monoclonal antibody (HB-22) and development of an enzyme-linked immunosorbent assay for human apolipoprotein A-I. Clin. Chem. 41:1895;1150.
19. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265.
20. Jin F.-Y., Kamanna V.S., Chuang M.-Y., Morgan K., Kashyap M.L. Gemfibrozil stimulates apolipoprotein AI synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (HEP G2). Arterioscler. Thromb. Vasc. Biol. 16:1996;1052.
21. Dixon J.L., Furukawa S., Ginsberg H.N. Oleate stimulates secretion of apolipoprotein B-containing lipoptotein from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem. 266:1991;5080.
22. Chomcynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156.
23. Brown T. Analysis of RNA by northern and slot hybridization. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K. Current Protocols in Molecular Biology. 1993;1-14 Wiley, Brooklyn, NY. ch 4, section 9.
24. Zannis V.I., Breslow J.L., San Giacomo T.R., Aden D.P., Knowles B.B. Characterization of the major apolipoproteins secreted by two human hepatoma cell lines. Biochemistry. 20:1981;2089.
25. Thrift R., Forte T.M., Cahoon B.E., Shore V.G. Characterization of lipoproteins produced by the human liver cell line, Hep G2 cell, under defined conditions. J. Lipid Res. 27:1986;236.
26. Jin F.-Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high density lipoprotein apolipoprotein AI but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 17:1997;2020.
27. Saku K., Gartside P.S., Hynd B.A., Kashyap M.L. Mechanism of action of Gemfibrozil on lipoprotein metabolism. J. Clin. Invest. 75:1985;1702.
28. Shepherd J., Packard C.J., Patsch J.R., Gotto A.M. Jr, Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and apolipoprotein A metabolism. J. Clin. Invest. 63:1979;858.
29. Packard C.J., Steward J.M., Third J.L.H.C., Morgan H.G., Lawrie T.D.V., Shepherd J. Effects of nicotinic acid therapy on high density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia. Biochim. Biophys. Acta. 618:1980;53.
30. Kaysen G.A., Hoye E., Jones H. Jr Apolipoprotein A-I levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Am. J. Physiol. 268:1995;F532.
31. Marshal J.F., Apostolopoulos J.J., Brack C.M., Howlett C.J. Regulation of apolipoprotein gene expression and plasma high density lipoprotein composition in experimental nephrosis. Biochim. Biophys. Acta. 1042:1990;271.
32. Marsh J.B., Sparks C.E. Lipoproteins in experimental nephrosis: plasma levels and composition. Metabolism. 28:1979;1040.
33. Marsh J.B., Drabkin D.K. Experimental reconstruction of metabolic patterns of lipid nephrosis. Key role of hepatic protein synthesis in hyperlipidemia. Metabolism. 9:1960;946.
34. Joven J., Espinel E., Simo J.M., Vilella E., Camps J., Oliver A. The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia. Atherosclerosis. 126:1996;243.
35. Joven J., Cliville X., Camps J., Espinel E., Simo J., Vilella E., Oliver A. Plasma protein abnormalities in nephrotic syndrome. Effect on plasma colloid osmotic pressure and viscosity. Clin. Chem. 43:1997;1223.
36. Marsh J.B., Sparks C.E. Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J. Clin. Invest. 64:1979;1229.
37. Boustani S., Ribeiro A., Janvier B., Loriette C., Bensman R., Druet P., Chambaz J., Mangeney M. Lipid synthesis and apolipoprotein gene expression in hepatocytes in primary culture from (puromycin-induced) nephrotic rats. Eur. J. Clin. Invest. 23:1993;211.
38. Maugeais C., Braschi S., Ouguerram K., Maugeais P., Mahot P., Jacotot B., Darmaun D., Magot T., Krempf M. Lipoprotein kinetics in patients with analbuminemia: evidence for the role of serum albumin in controlling lipoprotein metabolism. Arterioscler. Thromb. Vasc. Biol. 17:1997;1369-1375.
39. Yedgar S., Weinstein D.B., Patsch W., Schonfeld G., Casanada F.E., Steinberg D. Viscosity of culture medium as a regulator of synthesis and secretion of very low density lipoproteins by cultured hepatocytes. J. Biol. Chem. 257:1982;2188.
40. Yedgar S., Eilam O., Shafrir E. Regulation of plasma lipid levels by plasma viscosity in nephrotic rats. Am. J. Physiol. 248(1 pt 1):1985;E10.